Literature DB >> 2145936

Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts.

C C Scholz1, D P Berger, B R Winterhalter, H Henss, H H Fiebig.   

Abstract

The potential of evaluating the preclinical response of solid tumours was studied in human tumour xenografts in the clonogenic assay. Tumour specimens surgically removed from cancer patients were implanted subcutaneously into thymus-aplastic nude mice. Chemosensitivity of the mouse-grown tumours was tested with a modification of the double-layer soft-agar clonogenic assay. Tumour cells were tested against thirteen established cytostatic drugs at two dosages by continuous exposure. 62 retrospective in vivo/in vitro correlations were done. The clonogenic assay predicted correctly for clinical response in 16/27 (59%) and for resistance in 32/35 (91%). These correlation rates were similar to reported data for fresh solid human tumour specimens. The results support the clinical relevance of the nude mouse/clonogenic assay model.

Entities:  

Mesh：

Year:  1990        PMID： 2145936     DOI： 10.1016/0277-5379(90)90196-z

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  14 in total

1.  Mouse xenograft models vs GEM models for human cancer therapeutics.

Authors:  Ann Richmond; Yingjun Su
Journal:  Dis Model Mech       Date:  2008 Sep-Oct       Impact factor: 5.758

2.  Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma.

Authors:  Archana Vijaya Kumar; Carmen Donate; Beat A Imhof; Thomas Matthes
Journal:  J Vis Exp       Date:  2018-03-30       Impact factor: 1.355

3.  Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients.

Authors:  Chiara Grisanzio; Apryle Seeley; Michelle Chang; Michael Collins; Arianna Di Napoli; Su-Chun Cheng; Andrew Percy; Rameen Beroukhim; Sabina Signoretti
Journal:  J Pathol       Date:  2011-06-27       Impact factor: 7.996

Review 4.  Murine models to evaluate novel and conventional therapeutic strategies for cancer.

Authors:  James E Talmadge; Rakesh K Singh; Isaiah J Fidler; Avraham Raz
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

Review 5.  Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents.

Authors:  Sreenath V Sharma; Daniel A Haber; Jeff Settleman
Journal:  Nat Rev Cancer       Date:  2010-03-19       Impact factor: 60.716

Review 6.  Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF.

Authors:  Z A Antonello; C Nucera
Journal:  Oncogene       Date:  2013-12-23       Impact factor: 9.867

7.  Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3.

Authors:  Uddalak Bharadwaj; Min Li; Changyi Chen; Qizhi Yao
Journal:  Mol Cancer Res       Date:  2008-11       Impact factor: 5.852

Review 8.  Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells.

Authors:  Massimo Moro; Giulia Bertolini; Monica Tortoreto; Ugo Pastorino; Gabriella Sozzi; Luca Roz
Journal:  J Biomed Biotechnol       Date:  2012-04-04

9.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.

Authors:  J I Johnson; S Decker; D Zaharevitz; L V Rubinstein; J M Venditti; S Schepartz; S Kalyandrug; M Christian; S Arbuck; M Hollingshead; E A Sausville
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

Review 10.  Patient-derived breast tumor xenografts facilitating personalized cancer therapy.

Authors:  Melissa D Landis; Brian D Lehmann; Jennifer A Pietenpol; Jenny C Chang
Journal:  Breast Cancer Res       Date:  2013-01-22       Impact factor: 6.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.